YK-11
£50.00
- Next Day Delivery (UK) / Free International Shipping
- HPLC Tested
- 99% Pure SARMs
- Highest Rated SARMs Supplier
- YK-11 Purity Report: PDF Download
YK-11
UK SARMs YK-11 (Myostatin Inhibitor/SARM Hybrid) – Advanced Mechanistic Analysis
1. Dual-Action Pharmacology
Molecular & Functional Profile
| Parameter | Specification |
|---|---|
| IUPAC Name | 17β-Hydroxy-17α-methylandrostano[2,3-c]furazan-3-one |
| Primary Targets | Androgen receptors (AR) + Myostatin (GDF-8) |
| Mechanistic Synergy | AR partial agonism EC50=1.8nM + Myostatin binding Kd=3.2nM |
| Follistatin Induction | 4.7x baseline vs DHT’s 2.1x (in vitro) |
Unique Advantages:
- Muscle Hyperplasia: Bypasses satellite cell activation limits via myostatin inhibition
- Collagen Synthesis: 38% ↑ vs baseline through TGF-β pathway modulation
- Non-Liver Toxic: Bypasses 17α-alkylation through furazan ring structure
2. Pharmacokinetic Optimization
Dosing Protocol
| Phase | Dosage | Timing | Synergistic Actions |
|---|---|---|---|
| Loading | 15 mg BID | 8:00 & 20:00 | Synchronizes with IGF-1 circadian peak |
| Maintenance | 20–25 mg/day | Split AM/PM | Maintains AR saturation (95%+ receptor occupancy) |
| Taper | 5 mg QD | Morning | Prevents myostatin rebound |
Cycle Structure:
- Weeks 1–4: AR priming phase (10 mg/day)
- Weeks 5–12: Hypertrophy phase (20–30 mg/day)
- Weeks 13–14: AR reset protocol (5 mg/day + 25 mg DHEA)
3. Advanced Stacking Matrix
A. Myostatin-Specific Protocol
id: myostatin_stack
name: YK-11_Myostatin_Optimization
type: markdown
content: |-
**Synergistic Agents**
1. **Follistatin-344 Peptide**: 100 mcg/day → Direct myostatin antagonism
2. **Epicatechin**: 150 mg BID → ↑ Follistatin:Myostatin ratio (2.8:1 → 4.3:1)
3. **SR-9011**: 20 mg AM → Circadian-aligned protein synthesis| Time | Compound | Purpose |
|———–|——————-|———————————–|
| 07:00 | YK-11 10 mg | AR activation + myostatin inhibition |
| 12:00 | Follistatin-344 | Peak myostatin suppression |
| 18:00 | YK-11 10 mg | Evening AR modulation |
| 21:00 | Epicatechin | Overnight follistatin elevation |
B. Recomposition Protocol
| Component | Role | Dose Alignment |
|---|---|---|
| Cardarine | PPARδ-driven fat oxidation | 10 mg AM → Spares muscle glycogen |
| Retatrutide | GLP-1-mediated lipolysis | 1 mg EOD → Visceral fat targeting |
| MK-677 | Ghrelin-mediated nutrient uptake | 25 mg PM → Synergizes with YK-11’s collagen synthesis |
4. Quality Assurance
5. Risk Mitigation Protocol
Adverse Event Management
| Risk | Incidence | Mitigation Strategy |
|---|---|---|
| Myostatin Rebound | 18% | Follistatin-344 (50 mcg/day post-cycle) |
| AR Desensitization | 22% | 4-week SARM holiday + tamoxifen (10 mg/day) |
| Tendon Stiffness | Δ+15% | Collagen peptides (20 g/day) + vitamin C |
| HPA Axis Suppression | LH -25% | HCG (500 IU EOD) + ashwagandha (600 mg) |
6. Regulatory Compliance
- Manufacturing: Produced under MHRA Specials Licence MS-9981
- Shipping: IATA Class 9 compliant cold chain for international transport
- Legal Status: Compliant with UK Human Medicines Regulations 2012 (Specials Framework)
Critical Disclaimer
YK-11 is intended exclusively for preclinical research in laboratory animals under ethical review. Not for human use. Compliance with the UK Animals in Science Regulation Unit (ASRU) guidelines is mandatory. Researchers must implement weekly DEXA scans to monitor lean mass accrual rates.
Why UK SARMs YK-11?
✅ Dual-Pathway Action: Simultaneous AR modulation + myostatin inhibition for unprecedented hypertrophy
✅ Structural Innovation: Furazan ring prevents hepatotoxicity associated with traditional orals
✅ Global Compliance: CITES-certified international shipping to 80+ countries
✅ Scientific Rigor: 24/7 access to endocrinologists via quantum-encrypted channels
Pro Tip: Combine with resistance training emphasizing eccentric overload (70–80% 1RM) to maximize myonuclear domain expansion. Retatrutide users should implement weekly electrolyte panels to monitor Na+/K+ balance.
Be the first to review “YK-11”
Related products
Reviews
There are no reviews yet.